Allarity Therapeutics Inc
Change company Symbol lookup
Select an option...
ALLR Allarity Therapeutics Inc
SIVB SVB Financial Group
LYLT Loyalty Ventures Inc
NMRD Nemaura Medical Inc
LOGI Logitech International SA
BIOC Biocept Inc
KT KT Corp
SVRA Savara Inc
KA Kineta Inc
IMNM Immunome Inc
Go

*Nasdaq FSI: *Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements

Allarity Therapeutics, Inc. is a clinical-stage precision medicine company. The Company is engaged in targeting some of the unmet needs in oncology by developing differentiated and novel therapeutic candidates together with its Drug Response Predictor (DRP) companion diagnostics in a precision medicine approach. The Company's products include dovitinib, stenoparib, and IXEMPRA (ixabepilone). The lead therapeutic candidate, dovitinib, is a selective inhibitor of several classes of tyrosine kinases, including FGFR and VEGFR. The therapeutic candidate is stenoparib is a novel inhibitor of the key deoxyribonucleic acid (DNA) damage repair enzyme poly-ADP-ribose polymerase (PARP). The therapeutic candidate is IXEMPRA (ixabepilone) is a selective microtubule inhibitor. The DRP technology is a diagnostic platform that models human tumor biology and can help predict whether a cancer patient respond or not to a particular drug.

Closing Price: $0.1439

Day's Change: 0.0389 (37.05%)

Bid: --

Ask: --

B/A Size: --

Day's High: 0.229

Day's Low: 0.1301

Volume (Heavy Day) Volume: 83,434,571 10-day average volume: 8,156,624: 83,434,571

CBRE Group Inc. Cl A Stock Rises Friday, Outperforms Market

4:43 pm ET December 23, 2022 (MarketWatch) Print

This article was automatically generated by MarketWatch using technology from Automated Insights.

Shares of CBRE Group Inc. Cl A (CBRE) advanced 1.31% to $76.67 Friday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index rising 0.59% to 3,844.82 and the Dow Jones Industrial Average rising 0.53% to 33,203.93. CBRE Group Inc. Cl A closed $34.33 below its 52-week high ($111.00), which the company achieved on January 4th.

Trading volume (674,606) remained 1.0 million below its 50-day average volume of 1.7 M.

Data source: Dow Jones Market Data, FactSet. Data compiled December 23, 2022.

(END) Dow Jones Newswires

December 23, 2022 16:43 ET (21:43 GMT)

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for varies.

Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and